- Home
- PAAS vs RPRX Comparison
PAAS vs RPRX Comparison
Compare PAAS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAAS | RPRX |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 16.7B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PAAS | RPRX |
|---|---|---|
| Price | $54.07 | $44.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $51.80 | $47.75 |
| AVG Volume (30 Days) | ★ 10.2M | 3.9M |
| Earning Date | 02-18-2026 | 02-11-2026 |
| Dividend Yield | 0.88% | ★ 2.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.73 | ★ 1.75 |
| Revenue | ★ $3,254,800,000.00 | $2,349,844,000.00 |
| Revenue This Year | $27.28 | $38.81 |
| Revenue Next Year | $21.01 | $2.26 |
| P/E Ratio | $30.30 | ★ $25.18 |
| Revenue Growth | ★ 21.75 | 3.70 |
| 52 Week Low | $20.55 | $29.66 |
| 52 Week High | $69.99 | $44.36 |
Technical Indicators
Market Signals| Indicator | PAAS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 78.82 |
| Support Level | $52.16 | $40.16 |
| Resistance Level | $58.71 | $44.36 |
| Average True Range (ATR) | 3.63 | 0.66 |
| MACD | -1.32 | 0.38 |
| Stochastic Oscillator | 6.98 | 98.45 |
Price Performance
Historical ComparisonAbout PAAS Pan American Silver Corp.
Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.